SAGEbio
Cambridge, Massachusetts biotech developing Synbody modular biologics, with an anti-TL1A lead programme for inflammatory bowel and fibrotic disease.
Industry: Biotechnology (biologics for chronic inflammation) | Location: Cambridge, United States | Founded: 2022
About SAGEbio
SAGEbio is a biotechnology company that develops modular biologics intended to control chronic inflammation. Its website lists a Cambridge, Massachusetts address at 1 Broadway, and its LinkedIn page also lists a location in Thuwal, Saudi Arabia. LinkedIn gives 2022 as the founding year and a size of 2 to 10 employees, and describes the company as a research company focused on extending healthy life years.
The company's platform is built on Synbodies, which its website describes as single-domain synthetic antibodies linked to a domain that controls pharmacokinetics. LinkedIn adds that the platform draws on AI-supported antibody discovery and an in-house nanobody library. SAGEbio describes its team as cross-disciplinary, covering immunology, protein engineering and AI-assisted design, but names no individuals.
The lead programme is an anti-TL1A Synbody that targets the TL1A and DR3 axis, aimed at inflammatory bowel disease and fibrotic disease. LinkedIn says it is intended for subcutaneous use and that the company is seeking early-stage partners and investors to take its programmes into clinical trials. The website offers asset co-development, asset-centric deals, platform collaborations and discovery initiatives, and says the company works with academic centres, pharmaceutical companies and biotechnology firms, none of which are named.
No funding rounds, founders, executives or dated milestones are published on the pages read. The site footer is dated 2025.